Abstract:Abstract Background Metformin, a medication for type 2 diabetes, has been linked to many non-diabetes health benefits including increasing healthy lifespan. Previous work has only examined the benefits of metformin over periods of less than ten years, which may not be long enough to capture the true effect of this medication on longevity. Methods We searched medical records for Wales, UK, using the Secure Anonymised Information Linkage dataset for type 2 diabetes patients treated with metformin (N = 129,140) and sulphonylurea (N = 68,563). Non-diabetic controls were matched on sex, age, smoking, and history of cancer and cardiovascular disease. Survival analysis was performed to examine survival time after first treatment, using a range of simulated study periods. Findings Using the full twenty-year period, we found that type 2 diabetes patients treated with metformin had shorter survival time than matched controls, as did sulphonylurea patients. Metformin patients had better survival than sulphonylurea patients, controlling for age. Within the first three years, metformin therapy showed a benefit over matched controls, but this reversed after five years of treatment. Interpretation While metformin does appear to confer benefits to longevity in the short term, these initial benefits are outweighed by the effects of type 2 diabetes when patients are observed over a period of up to twenty years. Longer study periods are therefore recommended for studying longevity and healthy lifespan. Evidence before this study Work examining the non-diabetes outcomes of metformin therapy has suggested that there metformin has a beneficial effect on longevity and healthy lifespan. Both clinical trials and observational studies broadly support this hypothesis, but tend to be limited in the length of time over which they can study patients or participants. Added value of this study By using medical records we are able to study individuals with Type 2 diabetes over a period of two decades. We are also able to account for the effects of cancer, cardiovascular disease, hypertension, deprivation, and smoking on longevity and survival time following treatment. Implications of all the available evidence We confirm that there is an initial benefit to longevity of metformin therapy, but this benefit does not outweigh the negative effect on longevity of diabetes. Therefore, we suggest that longer study periods are required for inference to be made about longevity in future research.

A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan

Metformin Improves Cognition of Aged Mice by Promoting Cerebral Angiogenesis and Neurogenesis

Metformin's Mechanisms in Attenuating Hallmarks of Aging and Age-Related Disease.

Metformin: From diabetes to cancer to prolongation of life

228-LB: Metformin Alleviates Aging-Associated Metabolic Disorders through Intestinal AMPK-Mediated Gut Microbiome Alteration

Effect of Metformin on Cardiac Metabolism and Longevity in Aged Female Mice

A Mechanistic Analysis of Metformin's Biphasic Effects on Lifespan and Healthspan in C. Elegans: Elixir in Youth, Poison in Elder

The anti-aging role of metformin, clinical applications to pursue the longevity road

Comparison of long-term effects of metformin on longevity between people with type 2 diabetes and matched non-diabetic controls

Metformin Extends C. Elegans Lifespan Through Lysosomal Pathway.

Metformin: Sentinel of the Epigenetic Landscapes That Underlie Cell Fate and Identity

Metformin Protects PC12 Cells and Hippocampal Neurons from H2O2‐induced Oxidative Damage Through Activation of AMPK Pathway

Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis.

Metformin alleviates human cellular aging by upregulating the endoplasmic reticulum glutathione peroxidase 7

Repurposing metformin: an old drug with new tricks in its binding pockets

Metformin for Cardiovascular Protection, Inflammatory Bowel Disease, Osteoporosis, Periodontitis, Polycystic Ovarian Syndrome, Neurodegeneration, Cancer, Inflammation and Senescence: What Is Next?

Delaying Renal Aging: Metformin Holds Promise As a Potential Treatment

Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms

Metformin: An Old Drug with New Applications

Metformin as a Potential Prevention Strategy for Alzheimer's Disease and Alzheimer's Disease Related Dementias

Metformin Enhances Autophagy and Normalizes Mitochondrial Function to Alleviate Aging-Associated Inflammation